4.7 Article

Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical Trial

Journal

CLINICAL INFECTIOUS DISEASES
Volume 71, Issue 9, Pages 2375-2385

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciz1209

Keywords

cytomegalovirus; kidney transplantation; immune monitoring; cell-mediated immunity

Funding

  1. Instituto de Salud Carlos III (ISCIII) [ICI14/00242, PI16/01321]
  2. European Regional Development Fund, ERDF, a way to build Europe
  3. Biomarker-Driven Immunosuppression Minimization (BIO-DRIM) Consortium (EU FP7-health
  4. FP7/2007-2013) [305147]
  5. Department of Health of the Generalitat de Catalunya [SLT002/16/00183]
  6. Instituto de Salud Carlos III [INT15/00112, FI17/00233]
  7. Oxford Immunotec Ltd

Ask authors/readers for more resources

Background. Improving cytomegalovirus (CMV) immune-risk stratification in kidney transplantation is highly needed to establish guided preventive strategies. Methods. This prospective, interventional, multicenter clinical trial assessed the value of monitoring pretransplant CMV-specific cell-mediated immunity (CMI) using an interferon-gamma release assay to predict CMV infection in kidney transplantation. One hundred sixty donor/recipient CMV-seropositive (D+/R+) patients, stratified by their baseline CMV (immediate-early protein 1)-specific CMI risk, were randomized to receive either preemptive or 3-month antiviral prophylaxis. Also, 15-day posttransplant CMI risk stratification and CMI specific to the 65 kDa phosphoprotein (pp65) CMV antigen were investigated. Immunosuppression consisted of basiliximab, tacrolimus, mycophenolate mofetil, and corticosteroids in 80% of patients, whereas 20% received thymoglobulin induction therapy. Results. Patients at high risk for CMV based on pretransplant CMI developed significantly higher CMV infection rates than those deemed to be at low risk with both preemptive (73.3% vs 44.4%; odds ratio [OR], 3.44 [95% confidence interval {CI}, 1.30-9.08]) and prophylaxis (33.3% vs 4.1%; OR, 11.75 [95% CI, 2.31-59.71]) approaches. The predictive capacity for CMV-specific CMI was only found in basiliximab-treated patients for both preemptive and prophylaxis therapy. Fifteen-day CMI risk stratification better predicted CMV infection (81.3% vs 9.1%; OR, 43.33 [95% CI, 7.89-237.96]). Conclusions. Pretransplant CMV-specific CMI identifies D+/R+ kidney recipients at high risk of developing CMV infection if not receiving T-cell-depleting antibodies. Monitoring CMV-specific CMI soon after transplantation further defines the CMV infection prediction risk. Monitoring CMV-specific CMI may guide decision making regarding the type of CMV preventive strategy in kidney transplantation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Medicine, General & Internal

Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies: The Influence of TAC Exposure and Metabolism

Betty Chamoun, Irina B. Torres, Alejandra Gabaldon, Joana Sellares, Manel Perello, Eva Castella, Xavier Guri, Maite Salcedo, Nestor G. Toapanta, Ignacio Cidraque, Francesc Moreso, Daniel Seron

Summary: The combination of tacrolimus and mycophenolate is commonly used in renal transplants. The study found that tacrolimus exposure was associated with inflammation in healthy kidney areas, but not in scarred tissue.

JOURNAL OF CLINICAL MEDICINE (2021)

Article Immunology

Donor/Recipient HLA Molecular Mismatch Scores Predict Primary Humoral and Cellular Alloimmunity in Kidney Transplantation

Maria Meneghini, Elena Crespo, Matthias Niemann, Alba Torija, Nuria Lloberas, Vincent Pernin, Pere Fontova, Edoardo Melilli, Alexandre Fava, Nuria Montero, Anna Manonelles, Josep Maria Cruzado, Eduard Palou, Jaume Martorell, Josep Maria Grinyo, Oriol Bestard

Summary: Molecular HLA mismatches between donors and recipients may impact the development of posttransplant T-cell alloimmunity and subsequent donor-specific cellular and humoral alloimmune activation. These immune responses are influenced by the degree of HLA molecular incompatibility between donors and recipients, as well as the pretransplant cellular immune status of the patients.

FRONTIERS IN IMMUNOLOGY (2021)

Letter Surgery

Reconciling short-term clinical and immunological outcomes of SARS-CoV-2 vaccination in solid organ transplant recipients

Oriol Bestard, Thomas Jouve, Lluis Castells, Manuel Lopez, Marina Munoz, Elena Crespo, Nestor Toapanta, Juliana Esperalba, Isabel Campos-Varela, Teresa Pont, Oscar Len, Magda Campins, Francesc Moreso

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Editorial Material Urology & Nephrology

Impact of an article in the social age: Is tweeting the same as citing?

Marco Montomoli, Omar Taco Sanchez, Luis D'Marco, Jose Luis Gorriz Teruel

NEFROLOGIA (2022)

Editorial Material Transplantation

Navigating social media: how to ensure safe passage

Kate Stevens, Edoardo Melilli

NEPHROLOGY DIALYSIS TRANSPLANTATION (2022)

Article Surgery

Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study

Constantino Fernandez Rivera, Maria Calvo Rodriguez, Jose Luis Poveda, Julio Pascual, Marta Crespo, Gonzalo Gomez, Sheila Cabello Pelegrin, Javier Paul, Ricardo Lauzurica, Monica Perez Mir, Francesc Moreso, Manel Perello, Amado Andres, Esther Gonzalez, Ana Fernandez, Alicia Mendiluce, Beatriz Fernandez Carbajo, Ana Sanchez Fructuoso, Natividad Calvo, Alejandro Suarez, Gabriel Bernal Blanco, Antonio Osuna, M. Carmen Ruiz-Fuentes, Edoardo Melilli, Nuria Montero Perez, Ana Ramos, Beatriz Fernandez, Veronica Lopez, Domingo Hernandez

Summary: In a multicenter, prospective observational study, once-daily tacrolimus formulations were compared in de novo kidney transplant recipients. The LCPT group showed higher relative bioavailability than PR-Tac, with similar effectiveness in preventing rejection and comparable effects on renal function, safety, adherence, treatment failure, and discontinuation rates.

CLINICAL TRANSPLANTATION (2022)

Editorial Material Immunology

16th Congress of the Catalan Transplantation Society

Francesc J. Moreso

TRANSPLANTATION PROCEEDINGS (2022)

Article Medicine, Research & Experimental

High intrapatient variability of tacrolimus exposure associated with poorer outcomes in liver transplantation

Cristina Dopazo, Itxarone Bilbao, Sonia Garcia, Concepcion Gomez-Gavara, Mireia Caralt, Isabel Campos-Varela, Lluis Castells, Ernest Hidalgo, Francisco Moreso, Bruno Montoro, Ramon Charco

Summary: This study aimed to investigate the association between intrapatient variability (IPV) of tacrolimus pharmacokinetics at 6 months after liver transplantation (LT) and patient outcomes. The results suggest that high IPV between the third and sixth months after LT is associated with poorer patient survival rates and impaired renal function.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)

Article Urology & Nephrology

Effect of kidney replacement therapy modality after first kidney graft failure on second kidney transplantation outcomes

Carlos Couceiro, Ines Rama, Jordi Comas, Nuria Montero, Anna Manonelles, Sergi Codina, Alexandre Fava, Edoardo Melilli, Ana Coloma, Maria Quero, Jaume Tort, Josep M. Cruzado

Summary: This study compared the effects of different dialysis techniques after kidney transplant failure on patient survival and second kidney transplant outcomes, with results indicating that peritoneal dialysis is superior to hemodialysis in reducing mortality in candidates for a second kidney transplant without options for preemptive retransplantation.

CLINICAL KIDNEY JOURNAL (2022)

Article Medicine, General & Internal

Outcome of Kidney Transplants from Viremic and Non-Viremic Hepatitis C Virus Positive Donors into Negative Recipients: Results of the Spanish Registry

Antonio Franco, Francesc Moreso, Eulalia Sola-Porta, Isabel Beneyto, Nuria Esforzado, Francisco Gonzalez-Roncero, Asuncion Sancho, Edoardo Melilli, Juan Carlos Ruiz, Cristina Galeano

JOURNAL OF CLINICAL MEDICINE (2023)

Article Pharmacology & Pharmacy

The Effect of Intracellular Tacrolimus Exposure on Calcineurin Inhibition in Immediate- and Extended-Release Tacrolimus Formulations

Pere Fontova, Lisanne N. van Merendonk, Anna Vidal-Alabro, Raul Rigo-Bonnin, Gema Cerezo, Stefaan van Oevelen, Oriol Bestard, Edoardo Melilli, Nuria Montero, Ana Coloma, Anna Manonelles, Joan Torras, Josep M. Cruzado, Josep M. Grinyo, Helena Colom, Nuria Lloberas

Summary: Despite monitoring whole blood tacrolimus concentrations, acute rejection can still occur during tacrolimus therapy after kidney transplantation. This study aimed to investigate the intracellular pharmacokinetics (PK) of two tacrolimus formulations (immediate-release and extended-release) and their correlation with whole blood PK and pharmacodynamics (PD).

PHARMACEUTICS (2023)

Review Pediatrics

HLA (emphasis on DQ) compatibility for longer allograft survival in pediatric transplantation: Modern evidence and challenges

Maria Meneghini, Anat Roitberg Tambur

Summary: Kidney transplantation is the preferred treatment for children with end-stage kidney failure, but it faces obstacles such as suboptimal outcomes and the need for long-term immunosuppression. Improving HLA matching and utilizing HLA-DQ compatibility between recipient and donor in organ allocation schemes specifically for pediatric patients can enhance graft and patient outcomes. This review discusses recent literature on HLA matching in pediatric kidney transplantation and explores new approaches utilizing molecular mismatch load analysis.

PEDIATRIC TRANSPLANTATION (2023)

Article Microbiology

Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study)

Arnau Monforte, Ibai Los-Arcos, Maria Teresa Martin-Gomez, David Campany-Herrero, Judith Sacanell, Cristina Berastegui, Ester Marquez-Algaba, Abiu Sempere, Xavier Nuvials, Maria Deu, Lluis Castells, Francesc Moreso, Carles Bravo, Joan Gavalda, Oscar Len

Summary: We describe 53 solid organ transplant recipients treated with isavuconazole for fungal infections. There is scarce data of its use in solid organ transplant recipients, where interactions with calcineurin inhibitors and mTOR and adverse drug events have limited the use of other triazoles. To the best of our knowledge, this is the first article describing the safety regarding adverse events and drug interactions of isavuconazole for the treatment of fungal infections in a cohort of solid organ transplant recipients. Also, although this is a noncomparative study, we report some real world effectivity data of these patients, including treatment of non-Aspergillus fungal infections.

MICROBIOLOGY SPECTRUM (2022)

No Data Available